key: cord-0689326-60d2sryc
authors: Emadi, Seyed‐Naser; Hamzelou, Shahin; Saffarian, Zahra; Shakoei, Safoura
title: Challenges in the treatment of a patient with toxic epidermal necrolysis associated with COVID‐19: A case report
date: 2020-12-15
journal: Dermatol Ther
DOI: 10.1111/dth.14656
sha: b9ce3f46e90074c88630048bfc83062f226e845b
doc_id: 689326
cord_uid: 60d2sryc

nan

Challenges in the treatment of a patient with toxic epidermal necrolysis associated with COVID-19: A case report Dear Editor, In December 2019, a new coronavirus emerged in China and rapidly spread. 1 Currently, the outcome of COVID-19 patients treated with immunosuppression drugs is still unknown. Here, we report a 30-yearold woman, who was diagnosed with toxic epidermal necrolysis (TEN) and COVID-19 concurrently. The simultaneous treatment of these con- ities. Forty percent of the body area was involved. We decided to add cyclosporine (4 mg/kg) to the regimen, based on our successful experience of treating TEN patients. We confirmed COVID-19 infection twice, by using the polymerase chain reaction (PCR) assay.

The patient had been febrile (39 C-40 C) for 7 days, but she had not any respiratory symptoms. Her chest computerized tomography scan was normal. We had to consider both diseases. Based on the SCORTEN, we continued the administration of prednisolone and cyclosporine. On the fifth day, the progression of lesions was terminated.

Generally, TEN is a life-threatening severe cutaneous drug reaction. The mortality rate of this condition varies, based on SCORTEN. 2 In the Japanese study, the most common drugs for TEN were caused by phenobarbital, 3 and in the Switzerland study, there were no cases of TEN among patients who used topiramate. 4 Due to the concurrent initiation of both drugs, we cannot determine the exact cause of the drug. But according to studies, phenobarbital might play a greater role in causing disease.

On the other hand, COVID-19 produces an inflammatory environment that may reduce the threshold of drug reactions and may predispose the COVID patients to TEN.

F I G U R E 1 Bilateral conjunctivitis, hemorrhagic crusting of the lips, and the necrolytic epidermal detachment was observed on the upper extremities and the back

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: retrospective analysis of a cohort treated in a specialized referral center

Adverse cutaneous drug reactions associated with old-and newgeneration antiepileptic drugs using the Japanese Pharmacovigilance database

The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs

Managing cutaneous immune-mediated diseases during the COVID-19 pandemic

Comparison of efficacy of dexamethasone and methylprednisolone in improving PaO2/FiO2 ratio among COVID-19 patients

Influences of cyclosporin a and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication

Role of cyclophilin a during coronavirus replication and the antiviral activities of its inhibitors